Holen Sie sich die Stockscreener-App
2.97
0.68%
0.02
Handel nachbörslich:
2.97
Compass Therapeutics Inc Aktie (CMPX) Neueste Nachrichten
Earnings Chart Overlay Points to Compass Therapeutics Inc. UpsideMarket Trend Report & Growth Focused Stock Reports - thegnnews.com
Compass Therapeutics Reports Q2 2025 Financials and Clinical Progress - MSN
Compass Therapeutics price target raised to $12 from $10 at Guggenheim - MSN
Compass Therapeutics Announces Public Offering to Raise $112.5M - TipRanks
We are now beginning of Q3 2025, how following data readout was completed on Q4 2025? - AInvest
Who are the investors of CMPX - AInvest
Compass Therapeutics And 2 Other Promising Penny Stocks To Consider - Yahoo Finance
Real Time Data Flags Unusual Activity in Compass Therapeutics Inc.2025 Breakouts & Breakdowns & AI Enhanced Execution Alerts - sundaytimes.kr
Compass Therapeutics sells $120M in stock; RemeGen to seek China approval - Endpoints News
Compass Therapeutics: Finding Their Way With More Positive Updates In BTC - Seeking Alpha
Compass Therapeutics Posts Wider Q2 Loss - AOL.com
Compass, Inc. shares rise 2.48% premarket after Compass Therapeutics announced a $120 million public offering. - AInvest
Trend analysis for Compass Therapeutics Inc. this week2025 Key Lessons & Daily Technical Forecast Reports - Newser
Compass Therapeutics Faces Financial Risks Amid Global Economic Uncertainty and Trade Tensions - MSN
Compass Therapeutics dips 5%, prices $120M stock - MSN
Compass Therapeutics Announces Proposed Public Offering - GlobeNewswire
Compass Therapeutics' $120M Equity Raise: A Strategic Move for Pipeline Advancement or a Dilution Risk? - AInvest
Compass Therapeutics prices $120 million public offering of common stock By Investing.com - Investing.com Australia
Compass Therapeutics prices $120 million public offering of common stock - Investing.com
Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering - The Manila Times
Cancer Drug Developer Compass Therapeutics Secures $120M to Advance Commercial Plans - Stock Titan
Compass Therapeutics announces pricing of upsized $120 million public offering - MarketScreener
Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering - GlobeNewswire Inc.
Is Compass Therapeutics Inc. showing signs of accumulationControlled Entry Strategy With Safety Analytics - Newser
What recovery options are there for Compass Therapeutics Inc.Smart Entry Watchlist with Daily Analysis - Newser
Has Compass Therapeutics Inc. formed a bullish divergence [Treasury Yields]Free AI Driven Stock Price Forecasts - Newser
Compass Therapeutics Launches Public Offering of Common Shares - MarketScreener
Compass Therapeutics announces public offering of common stock By Investing.com - Investing.com India
Heatmap analysis for Compass Therapeutics Inc. and competitorsFree Stock Screener With Smart Filters - Newser
Compass Therapeutics Plans Stock Offering to Fund Cancer Drug Development - Stock Titan
Will Compass Therapeutics Inc. bounce back from current supportDaily Technical Chart Pattern Analysis Report - Newser
Compass Therapeutics: D. Boral Capital maintains Buy, PT raised to $32. - AInvest
A Quick Look at Today's Ratings for Compass Therapeutics(CMPX.US), With a Forecast Between $7 to $24 - 富途牛牛
Compass Therapeutics: Guggenheim Raises PT to $12, Maintains Buy Rating - AInvest
Compass Therapeutics shares rise 1.20% premarket after reporting Q2 earnings and business update. - AInvest
Compass Therapeutics Inc (CMPX) Stock: A Year of Declines and Increases - investchronicle.com
Guggenheim raises Compass Therapeutics stock price target on promising clinical data - Investing.com Canada
Institutional Investors Have a Lot Riding on Compass Therapeutics, Inc. (NASDAQ:CMPX) With 46% Ownership - 富途牛牛
What makes Compass Therapeutics Inc. stock price move sharplyRisk/Reward Optimization Entry Point Analysis - Newser
Compass Therapeutics Inc (CMPX) Q2 2025 Earnings Call Highlights: Promising Clinical Advances ... By GuruFocus - Investing.com Canada
What does recent volatility data suggest for Compass Therapeutics Inc.Portfolio Risk Distribution Analysis Tool - Newser
Compass Therapeutics: Promising Pipeline and Strong Financial Outlook Drive Buy Rating - AInvest
Using data filters to optimize entry into Compass Therapeutics Inc.Free Short Term High Yield Stock Tips - Newser
Using Ichimoku Cloud for Compass Therapeutics Inc. technicalsHigh Conviction Screener with Trend Matching - Newser
Compass Therapeutics Q2 2025 Earnings Call Transcript - MarketBeat
Compass Therapeutics Soars 20.5% on Groundbreaking Clinical Data—What’s Next for the Biotech? - AInvest
Compass Therapeutics' shares rise 21% on positive pipeline updates. - AInvest
Compass Therapeutics stock rises on pipeline updates (CMPX) - Seeking Alpha
Compass Therapeutics Gains on Positive Cancer-Drug Survival Data - 富途牛牛
Compass Therapeutics Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
How to integrate Compass Therapeutics Inc. into portfolio analysis toolsFree Investment Plan With Growth Optimization - Newser
Transcript : Compass Therapeutics, Inc.Special Call - MarketScreener
Earnings call transcript: Compass Therapeutics Q2 2025 misses EPS expectations - Investing.com
Compass Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Can volume confirm reversal in Compass Therapeutics Inc.Free Beginner Friendly Stock Selection Guide - Newser
What to expect from Compass Therapeutics Inc. in the next 30 daysReal-Time Equity Price Action Analysis - Newser
Compass Therapeutics Reports Promising Q2 2025 Results - TipRanks
Compass Therapeutics Grows R&D Spend And Extends Cash Runway - Finimize
Compass Therapeutics Reports Q2 Net Loss of $19.9mln - AInvest
Compass Therapeutics Q2 net loss widens to $19.9 mln - MarketScreener
Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update - GlobeNewswire
Compass Therapeutics, Inc. SEC 10-Q Report - TradingView
Is a relief rally coming for Compass Therapeutics Inc. holdersIntraday Price Forecast Using Volume Models - Newser
0.44%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):